NasdaqGS:AGIOBiotechs
Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug
Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.
This approval, supported by global Phase 3 ENERGIZE and ENERGIZE-T data and backed by a regional partnership with NewBridge Pharmaceuticals, strengthens Agios’s push into Gulf markets for rare blood disorder treatments.
Next, we’ll examine...